Last reviewed · How we verify

1 mg.kg-1 bupivacaine 0.125%

Istanbul University · Phase 1 active Small molecule Quality 0/100

1 mg.kg-1 bupivacaine 0.125% is a Small molecule drug developed by Istanbul University. It is currently in Phase 1 development. Also known as: Marcaine.

At a glance

Generic name1 mg.kg-1 bupivacaine 0.125%
Also known asMarcaine
SponsorIstanbul University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 1 mg.kg-1 bupivacaine 0.125%

What is 1 mg.kg-1 bupivacaine 0.125%?

1 mg.kg-1 bupivacaine 0.125% is a Small molecule drug developed by Istanbul University.

Who makes 1 mg.kg-1 bupivacaine 0.125%?

1 mg.kg-1 bupivacaine 0.125% is developed by Istanbul University (see full Istanbul University pipeline at /company/istanbul-university).

Is 1 mg.kg-1 bupivacaine 0.125% also known as anything else?

1 mg.kg-1 bupivacaine 0.125% is also known as Marcaine.

What development phase is 1 mg.kg-1 bupivacaine 0.125% in?

1 mg.kg-1 bupivacaine 0.125% is in Phase 1.

Related